Ligand id: 6891
Name: abatacept
View more information in the IUPHAR Pharmacology Education Project: abatacept
Classification ![]() |
|
Compound class | Antibody |
Ligand families/groups | Immune checkpoint modulators |
Approved drug? | Yes (FDA (2005), EMA (2005)) |
International Nonproprietary Names ![]() |
|
INN number | INN |
8495 | abatacept |
Synonyms ![]() |
BMS-188667 | CTLA4-IgG4m | Orencia® | RG-1046 | RG-2077 |
Comments |
Abatacept is a recombinant protein fusing the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) [3]. In essence, abatacept is a CTLA-4 mimetic, that enhances CTLA-4's inhibitory signal to T cells, thereby down-modulating T cell mediated inflammation. |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 212 |
Other databases | |
ChEMBL Ligand | CHEMBL1201823 (Hs) |
DrugBank Ligand | DB01281 |
GtoPdb PubChem SID | 178103473 |
PubChem SID | 135355129 |
Search PubMed clinical trials | abatacept |
Search PubMed titles | abatacept |
Search PubMed titles/abstracts | abatacept |
Wikipedia | Abatacept |